143 related articles for article (PubMed ID: 25737620)
1. Ovarian masses: changing clinico histopathological trends.
Sharadha S; Sridevi TA; Renukadevi TK; Gowri R; Binayak D; Indra V
J Obstet Gynaecol India; 2015 Feb; 65(1):34-8. PubMed ID: 25737620
[TBL] [Abstract][Full Text] [Related]
2. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital of eastern India.
Mondal SK; Banyopadhyay R; Nag DR; Roychowdhury S; Mondal PK; Sinha SK
J Cancer Res Ther; 2011; 7(4):433-7. PubMed ID: 22269405
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of intraoperative frozen section for the evaluation of ovarian neoplasms: an institutional experience.
Hashmi AA; Naz S; Edhi MM; Faridi N; Hussain SD; Mumtaz S; Khan M
World J Surg Oncol; 2016 Mar; 14():91. PubMed ID: 27029917
[TBL] [Abstract][Full Text] [Related]
4. Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors: A Distribution Pattern in a Tertiary Care Center.
Mehra P; Aditi S; Prasad KM; Bariar NK
Cureus; 2023 Apr; 15(4):e38273. PubMed ID: 37255899
[TBL] [Abstract][Full Text] [Related]
5. Clinico-histopathological analysis of neoplastic and non-neoplastic lesions of the ovary: a 3-year prospective study in dhule, north maharashtra, India.
S N K; N V D; P N D; D B N; K H S
J Clin Diagn Res; 2014 Aug; 8(8):FC04-7. PubMed ID: 25302198
[TBL] [Abstract][Full Text] [Related]
6. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
7. Histopathological pattern of ovarian neoplasms and their age distribution in the western region of Saudi Arabia.
Abdullah LS; Bondagji NS
Saudi Med J; 2012 Jan; 33(1):61-5. PubMed ID: 22273650
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of ovarian tumors: Histopathological study of 218 cases.
Mansoor NA; Jezan HS
Gulf J Oncolog; 2015 May; 1(18):64-70. PubMed ID: 26003107
[TBL] [Abstract][Full Text] [Related]
9. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
[TBL] [Abstract][Full Text] [Related]
11. Calcifications in mucinous and serous cystic ovarian tumors.
Okada S; Ohaki Y; Inoue K; Kawamura T; Hayashi T; Kato T; Kumazaki T
J Nippon Med Sch; 2005 Feb; 72(1):29-33. PubMed ID: 15834205
[TBL] [Abstract][Full Text] [Related]
12. Periodic acid-Schiff stain as a prognostic indicator in serous and mucinous ovarian tumors.
Aalto ML; Collan Y
Int J Gynaecol Obstet; 1986 Feb; 24(1):27-34. PubMed ID: 2874066
[TBL] [Abstract][Full Text] [Related]
13. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
15. Pathological Features of Ovarian Tumors, Diagnosed at a Tertiary Care Hospital in Afghanistan: A Cross-sectional Study.
Ibrahimkhil AS; Malakzai HA; Haidary AM; Hussaini N; Abdul-Ghafar J
Cancer Manag Res; 2022; 14():3325-3333. PubMed ID: 36465710
[TBL] [Abstract][Full Text] [Related]
16. Aurora-A kinase is differentially expressed in the nucleus and cytoplasm in normal Müllerian epithelium and benign, borderline and malignant serous ovarian neoplasms.
Alkhateeb KJ; Crane JE; Sak M; Jorgensen CJ; O'Donnell JP; Zumbar CT; Wozniak JA; Salazar CR; Parwani AV; Lehman NL
Diagn Pathol; 2021 Oct; 16(1):98. PubMed ID: 34706741
[TBL] [Abstract][Full Text] [Related]
17. DNA Cytometry and Nuclear Morphometry in Ovarian Benign, Borderline and Malignant Tumors.
El Din AA; Badawi MA; Aal SE; Ibrahim NA; Morsy FA; Shaffie NM
Open Access Maced J Med Sci; 2015 Dec; 3(4):537-44. PubMed ID: 27275284
[TBL] [Abstract][Full Text] [Related]
18. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
19. Ovarian masses in children: a review of 91 cases of malignant and benign masses.
Brown MF; Hebra A; McGeehin K; Ross AJ
J Pediatr Surg; 1993 Jul; 28(7):930-3. PubMed ID: 8229571
[TBL] [Abstract][Full Text] [Related]
20. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
Kim DJ; Lee MH; Park TI; Bae HI
J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
